ARTHUR-D.-LITTLE
Whatever the success of climate change mitigation measures, companies and society will need to adapt to a changing world. To aid business climate change adaptation strategies, Arthur D. Little (ADL)’s Blue Shift Institute today published We’re doomed, now what?, an in-depth report that sets out five potential scenarios for adaptation and highlights relevant technologies to focus on.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240627698200/en/
Arthur D. Little Blue Shift Institute Report Outlines 5 Scenarios for Future of Climate Change Adaptation (Graphic: Business Wire)
The report is based on extensive analysis, interviews with over 40 international experts, surveys of business leaders, and was created in close collaboration with the United Nation’s (UN’s) World Intellectual Property Organization (WIPO).
It works on a “+3°C by 2100” outcome for climate change, based on projections by the Intergovernmental Panel on Climate Change (IPCC) and uses this to underpin five potential, non-exclusive scenarios for the future of climate change adaptation:
- Green Communities: A resource-scarce world in which grassroots initiatives flourish, for lack of more ambitious projects; there is a pull towards greater decentralization, circularity, and frugality
- Lonely at the top: Highly concentrated and competitive industries in which market leaders spearhead adaptation to build competitive advantage and keep satisfying consumers, while operating under increasing constraints
- Wild Green West: A creative chaos in which private adaptation initiatives sprout everywhere, fueled by private capital and hype, with no overarching strategy or consistency
- Don’t Look Up: A bleak future in which neither customers nor finance institutions have adjusted to the new climate reality, leaving nothing but quick fixes and crisis management
- Adaptation Surge: A world in which adaptation is the norm and the new currency, resetting expectations, creating new markets and new needs for differentiation, and possibly overengineering
For each of these futures the report outlines the functional expectations and relevant technologies to drive adaptation. Alongside this, it includes “no regret” solutions, enabling technologies, and capabilities that will be vital, whatever the future brings, and that companies should invest in now.
Dr. Albert Meige, Global Director of Blue Shift at Arthur D. Little, comments: “When faced with prospective technology choices, executives often need to address three challenges: complexity, speed and cognition. Adaptation to climate change is no different. It is complex because climate impacts are local, multifactorial and highly variable; and also because there is a myriad of adaptation technologies available. By modeling potential scenarios we aim to cut through this complexity, providing CEOs with a clear guide to the potential technologies that their adaptation will require.”
Dr. Peter Oksen, Senior Program Officer at the World Intellectual Property Organization (WIPO) GREEN, comments: “This report offers a refreshing new angle to climate action, namely that of businesses and their priorities for adapting to a challenging future. It provides the scenario-based context for the technologies outlined by WIPO GREEN, underscoring the essential role of innovation in forging a sustainable future. By detailing the functional expectations and key technologies necessary for adaptation, it highlights the need to integrate technological advancements within our business, economic and policy frameworks to effectively combat climate change.”
We’re doomed, now what? can be accessed here: https://tinyurl.com/4w35xahm
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627698200/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 18:07:00 CET | Press release
Through AI, Siemens and NVIDIA are reinventing the entire end-to-end industrial value chain – from design and engineering to manufacturing, production, operations, and into supply chainsSiemens and NVIDIA to build AI-accelerated portfolio including AI-native electronic design, AI native simulation as well as AI driven adaptive manufacturing and supply chainSiemens and NVIDIA to design the next generation of AI factoriesSiemens and NVIDIA to optimize operations through shared innovation CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
